Bausch + Lomb Higher in U.S. Pre-market After Posting Increase in Q4 Adjusted Profit, Revenue

MT Newswires

02-19

Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.

Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.

Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter

Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion.

"Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs."

The company's shares were last seen up US$0.52, to US$16.87, in New York trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512017851"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512017851\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512017851?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 20:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2512017851","market":"us","top_or_hot":-1,"title":"Bausch + Lomb Higher in U.S. Pre-market After Posting Increase in Q4 Adjusted Profit, Revenue","media":"MT Newswires","content":"<html><body><p>Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.\n<br/>\n<br/> Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.\n<br/>\n<br/> Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter\n<br/>\n<br/> Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion. \n<br/>\n<br/> \"Underpinning our recent success is a commitment to long-term, profitable growth,\" said Brent Saunders, chairman and CEO, Bausch + Lomb. \"Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.\"\n<br/>\n<br/> The company's shares were last seen up US$0.52, to US$16.87, in New York trading.\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch + Lomb Higher in U.S. Pre-market After Posting Increase in Q4 Adjusted Profit, Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch + Lomb Higher in U.S. Pre-market After Posting Increase in Q4 Adjusted Profit, Revenue\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MT Newswires</strong><span class=\"h-time small\">2025-02-19 20:45</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.\n<br/>\n<br/> Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.\n<br/>\n<br/> Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter\n<br/>\n<br/> Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion. \n<br/>\n<br/> \"Underpinning our recent success is a commitment to long-term, profitable growth,\" said Brent Saunders, chairman and CEO, Bausch + Lomb. \"Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.\"\n<br/>\n<br/> The company's shares were last seen up US$0.52, to US$16.87, in New York trading.\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/bausch-lomb-higher-u-pre-124510413.html\">MT Newswires</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHC","symbol_name":"Bausch Health Companies Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/bausch-lomb-higher-u-pre-124510413.html","article_id":"2512017851","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512017851","pubTimestamp":1739969110,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bausch + Lomb  traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter. Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion.\"Underpinning our recent success is a commitment to long-term, profitable growth,\" said Brent Saunders, chairman and CEO, Bausch + Lomb. \"Our refocused pipeline is now filled with promise and potential to significantly enhanc","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BHC":"Bausch Health Companies Inc"},"translate_title":"博士伦公布第四季度调整后利润和收入增长后，美国盘前股价走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHC":0.9},"content_text":"Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.\n\n Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.\n\n Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter\n\n Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion. \n\n \"Underpinning our recent success is a commitment to long-term, profitable growth,\" said Brent Saunders, chairman and CEO, Bausch + Lomb. \"Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs.\"\n\n The company's shares were last seen up US$0.52, to US$16.87, in New York trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}